Abstract:Highlights This study is the first to evaluate the effects of multiple daily injection and continuous subcutaneous insulin infusion therapy among Chinese pregnant women with type 1 diabetes. We found that pregnant women with type 1 diabetes on continuous subcutaneous insulin infusion therapy had better glycemic control in the third trimester than those on multiple daily injection therapy. Continuous subcutaneous insulin infusion users had a significant decline in glycated hemoglobin (HbA1c) level from preconception to the third trimester. There was a nonsignificant lower HbA1c level for women treated with long‐acting insulin, compared with neutral protamine Hagedorn. Introduction The study aimed to compare glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus (T1DM) using multiple daily injection therapy (MDI) and continuous subcutaneous insulin infusion (CSII) and to compare outcomes of women treated with long‐acting insulin or neutral protamine Hagedorn (NPH). Methods This multicenter prospective cohort study involved women with pregestational T1DM treated with MDI and CSII. Primary outcome was glycated hemoglobin (HbA1c) before and during pregnancy. Secondary outcomes included maternal and neonatal outcomes and quality of life. Results Of the 121 studied women, the average age was 28.48 years, and the average body mass index was 21.29 kg/m2 at conception and 26.32 kg/m2 at delivery. Of the studied women, 78.51% had planned pregnancy. Women treated with MDI and CSII had comparable HbA1c before pregnancy or in the first and second trimesters. In the third trimester, women on CSII therapy had significantly lower HbA1c (6.07 ± 0.62 vs 6.20 ± 0.88%, p = .017), higher HbA1c on‐target rate (71.43% vs 64.62%, p = .030), and greater decline of HbA1c from preconception to the third trimester (−0.65 vs −0.30%, p = .047). Fewer daily insulin requirements were observed in those used CSII compared with MDI‐treated women (0.60 ± 0.22 vs 0.73 ± 0.25 U/kg/day, p = .004). Newborns born of mothers treated with the CSII method were more likely to have neonatal jaundice (adjusted odds ratio [OR] 2.76, 95% confidence interval [CI] 1.16–6.57) and neonatal intensive care unit (adjusted OR 3.73, 95%CI 1.24–11.16), and women on CSII had lower scores in patient‐reported quality of life (p = .045). In the MDI group, those receiving long‐acting insulin had nonsignificant lower HbA1c and higher HbA1c on‐target rate in the second and third trimesters, compared with those treated with NPH. Conclusions Insulin pump users may achieve better glycemic control than multiple daily insulin injections, which did not substantially improve pregnancy outcome.

Clinical Evaluation of Continuous Subcutaneous Insulin Infusion for Patients with Gestational Diabetes Mellitus

Clinical observation and nursing care on patients with type 2 diabetes applied as continuous subcutaneous insulin infusion

Comparative effects of insulin pump and injection on gestational diabetes mellitus pregnancy outcomes and serum biomarkers

Continuous subcutaneous insulin infusion versus multiple daily injection therapy in pregnant women with type 1 diabetes

Detection of insulin level and its significance in OGTT in pregnant women with gestational diabetes mellitus

Comparison Between Insulin Pump Therapy and Conventional Subcutaneous Insulin Infusion Therapy for Gestational Diabetes Mellitus:A Systematic Review

Effect of Integrated Intervention for Patients with Gestational Diabetes Mellitus Undergoing Predelivery Insulin Pump Intensive Therapy

Effect of treating hyperglycemia of type 2 diabetes with continuous subcutaneous insulin infusion

Subcutaneous continuous insulin infusion and control of blood glucose concentration in diabetics in third trimester of pregnancy.

Application of Continuous Subcutaneous Insulin Infusion in Newly Versus Previously Diagnosed Type 2 Diabetes

The Effects of Continuous Subcutaneous Insulin Infusion on Metabolism of Glucose and Lipid in Patients with Type 2 Diabetes

Efficacy of Continuous Glucose Monitoring System Combined with Insulin Pump in Diabetic Pafients Aged 60 Years and Over

Study on the therapeutic effect of insulin pump in the treatment of type 1 diabetes

Effect of Continuous Subcutaneous Injection of Insulin Analogues in Pregnant Women with Diabetes Mellitus Complicated with Ketoacidosis

Clinical effect and safety of continuous subcutaneous insulin infusion in elderly patients with type 2 diabetes

Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes

The Application of Insulin Pump in Diabetic Patients

[Evaluating the Feature of Hypoglycemia Detected by Continuous Glucose Monitoring System During Temporary Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Patients].

Therapeutic characteristics of patients with gestational diabetes mellitus receiving insulin treatment during pregnancy: a retrospective study

Comparison of the efficacy between short term intensive therapy by insulin pump and multiple subcutaneous insulin injections

Clinical application of continuous subcutaneous insulin infusion in elderly type 2 diabetic patients